Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More
Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
LUPIN Mar-20 |
ADCOCK INGRAM Jun-14 |
LUPIN/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 882 | 383 | - | |
Low | Rs | 505 | 276 | - | |
Sales per share (Unadj.) | Rs | 339.4 | 113.9 | - | |
Earnings per share (Unadj.) | Rs | -5.9 | -28.7 | - | |
Cash flow per share (Unadj.) | Rs | 15.5 | -23.8 | - | |
Dividends per share (Unadj.) | Rs | 6.00 | 0 | - | |
Dividend yield (eoy) | % | 0.9 | 0 | - | |
Book value per share (Unadj.) | Rs | 276.7 | 89.4 | - | |
Shares outstanding (eoy) | m | 453.00 | 168.78 | - | |
Bonus/Rights/Conversions | ESOP | - | - | ||
Price / Sales ratio | x | 2.0 | 2.9 | 70.6% | |
Avg P/E ratio | x | -116.6 | -11.5 | 1,015.7% | |
P/CF ratio (eoy) | x | 44.8 | -13.9 | -323.6% | |
Price / Book Value ratio | x | 2.5 | 3.7 | 68.0% | |
Dividend payout | % | -100.9 | 0 | - | |
Avg Mkt Cap | Rs m | 314,201 | 55,608 | 565.0% | |
No. of employees | `000 | 18.3 | 4.3 | 426.3% | |
Total wages/salary | Rs m | 29,868 | 3,490 | 855.8% | |
Avg. sales/employee | Rs Th | 8,400.6 | 4,476.9 | 187.6% | |
Avg. wages/employee | Rs Th | 1,632.0 | 813.0 | 200.7% | |
Avg. net profit/employee | Rs Th | -147.2 | -1,128.1 | 13.0% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 153,748 | 19,219 | 800.0% | |
Other income | Rs m | 4,838 | 135 | 3,594.4% | |
Total revenues | Rs m | 158,585 | 19,354 | 819.4% | |
Gross profit | Rs m | 24,849 | -3,331 | -746.1% | |
Depreciation | Rs m | 9,702 | 829 | 1,169.7% | |
Interest | Rs m | 3,630 | 521 | 697.2% | |
Profit before tax | Rs m | 16,355 | -4,546 | -359.8% | |
Minority Interest | Rs m | 4 | -13 | -30.8% | |
Prior Period Items | Rs m | 39 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | -7,521 | 0 | - | |
Tax | Rs m | 11,571 | 284 | 4,073.4% | |
Profit after tax | Rs m | -2,694 | -4,843 | 55.6% | |
Gross profit margin | % | 16.2 | -17.3 | -93.3% | |
Effective tax rate | % | 70.8 | -6.2 | -1,132.3% | |
Net profit margin | % | -1.8 | -25.2 | 7.0% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 154,132 | 14,076 | 1,095.0% | |
Current liabilities | Rs m | 92,252 | 7,920 | 1,164.8% | |
Net working cap to sales | % | 40.2 | 32.0 | 125.6% | |
Current ratio | x | 1.7 | 1.8 | 94.0% | |
Inventory Days | Days | 82 | 111 | 74.0% | |
Debtors Days | Days | 129 | 124 | 104.3% | |
Net fixed assets | Rs m | 89,082 | 8,205 | 1,085.7% | |
Share capital | Rs m | 906 | 89 | 1,015.3% | |
Net worth | Rs m | 125,367 | 15,085 | 831.1% | |
Long term debt | Rs m | 17,933 | 5,301 | 338.3% | |
Total assets | Rs m | 249,839 | 28,497 | 876.7% | |
Interest coverage | x | 5.5 | -7.7 | -71.2% | |
Debt to equity ratio | x | 0.1 | 0.4 | 40.7% | |
Sales to assets ratio | x | 0.6 | 0.7 | 91.2% | |
Return on assets | % | 0.4 | -15.2 | -2.5% | |
Return on equity | % | -2.1 | -32.1 | 6.7% | |
Return on capital | % | 8.7 | -19.8 | -44.1% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 14,688 | 1,640 | 895.4% | |
From Investments | Rs m | 11,070 | -504 | -2,197.7% | |
From Financial Activity | Rs m | -8,906 | 4,811 | -185.1% | |
Net Cashflow | Rs m | 16,853 | 5,948 | 283.3% |
Compare LUPIN With: MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Compare LUPIN With: FDC BIOCON WYETH DISHMAN PHARMA IPCA LABS
Indian share markets witnessed volatile trading activity throughout the day today and ended lower.
Here's an analysis of the annual report of LUPIN for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.
For the quarter ended September 2020, LUPIN has posted a net profit of Rs 2 bn (up 271.3% YoY). Sales on the other hand came in at Rs 38 bn (down 12.0% YoY). Read on for a complete analysis of LUPIN's quarterly results.
For the quarter ended June 2020, LUPIN has posted a net profit of Rs 1 bn (down 64.2% YoY). Sales on the other hand came in at Rs 35 bn (down 20.2% YoY). Read on for a complete analysis of LUPIN's quarterly results.
Here's an analysis of the annual report of LUPIN for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.
More Views on NewsAjit Dayal on how India's vaccine strategy will impact the markets.
Narayana Murthy was one of the first unicorn founders to get the backing of this entity...
There is no stopping this 11-bagger stock from significant upside.
In this video I tell you the three Nifty ETFs I think are the best.
In this video, I'll you what I think is the real reason behind yesterday's market crash.
More